Global Monoclonal Antibody Production Service Market Outlook, In‑Depth Analysis & Forecast to 2031

1 Study Coverage
1.1 Introduction to Monoclonal Antibody Production Service: Definition, Properties, and Key Attributes
1.2 Market Segmentation by Type
1.2.1 Global Monoclonal Antibody Production Service Market Size by Type, 2020 VS 2024 VS 2031
1.2.2 Rabbit Monoclonal Antibodies
1.2.3 Mouse Monoclonal Antibodies
1.2.4 Human Monoclonal Antibodies
1.2.5 Others
1.3 Market Segmentation by Application
1.3.1 Global Monoclonal Antibody Production Service Market Size by Application, 2020 VS 2024 VS 2031
1.3.2 Biotechnology
1.3.3 Medical
1.3.4 University
1.3.5 Others
1.4 Assumptions and Limitations
1.5 Study Objectives
1.6 Years Considered
2 Executive Summary
2.1 Global Monoclonal Antibody Production Service Revenue Estimates and Forecasts 2020-2031
2.2 Global Monoclonal Antibody Production Service Revenue by Region
2.2.1 Revenue Comparison: 2020 VS 2024 VS 2031
2.2.2 Historical and Forecasted Revenue by Region (2020-2031)
2.2.3 Global Revenue Market Share by Region (2020-2031)
2.2.4 Emerging Market Focus: Growth Drivers & Investment Trends
3 Competition by Players
3.1 Global Monoclonal Antibody Production Service Player Revenue Rankings and Profitability
3.1.1 Global Revenue (Value) by Players (2020-2025)
3.1.2 Global Key Player Revenue Ranking (2023 vs. 2024)
3.1.3 Revenue-Based Tier Segmentation (Tier 1, Tier 2, and Tier 3)
3.1.4 Gross Margin by Top Player (2020 VS 2024)
3.2 Global Monoclonal Antibody Production Service Companies Headquarters and Service Footprint
3.3 Main Product Type Market Size by Players
3.3.1 Rabbit Monoclonal Antibodies Market Size by Players
3.3.2 Mouse Monoclonal Antibodies Market Size by Players
3.3.3 Human Monoclonal Antibodies Market Size by Players
3.3.4 Others Market Size by Players
3.4 Global Monoclonal Antibody Production Service Market Concentration and Dynamics
3.4.1 Global Market Concentration (CR5 and HHI)
3.4.2 Entrant/Exit Impact Analysis
3.4.3 Strategic Moves: M&A, Expansion, R&D Investment
4 Global Product Segmentation Analysis
4.1 Global Monoclonal Antibody Production Service Revenue Trends by Type
4.1.1 Global Historical and Forecasted Revenue by Type (2020-2031)
4.1.2 Global Revenue Market Share by Type (2020-2031)
4.2 Key Product Attributes and Differentiation
4.3 Subtype Dynamics: Growth Leaders, Profitability and Risk
4.3.1 High-Growth Niches and Adoption Drivers
4.3.2 Profitability Hotspots and Cost Drivers
4.3.3 Substitution Threats
5 Global Downstream Application Analysis
5.1 Global Monoclonal Antibody Production Service Revenue by Application
5.1.1 Global Historical and Forecasted Revenue by Application (2020-2031)
5.1.2 Revenue Market Share by Application (2020-2031)
5.1.3 High-Growth Application Identification
5.1.4 Emerging Application Case Studies
5.2 Downstream Customer Analysis
5.2.1 Top Customers by Region
5.2.2 Top Customers by Application
6 North America
6.1 North America Market Size (2020-2031)
6.2 North America Key Players Revenue in 2024
6.3 North America Monoclonal Antibody Production Service Market Size by Type (2020-2031)
6.4 North America Monoclonal Antibody Production Service Market Size by Application (2020-2031)
6.5 North America Growth Accelerators and Market Barriers
6.6 North America Monoclonal Antibody Production Service Market Size by Country
6.6.1 North America Revenue Trends by Country
6.6.2 US
6.6.3 Canada
6.6.4 Mexico
7 Europe
7.1 Europe Market Size (2020-2031)
7.2 Europe Key Players Revenue in 2024
7.3 Europe Monoclonal Antibody Production Service Market Size by Type (2020-2031)
7.4 Europe Monoclonal Antibody Production Service Market Size by Application (2020-2031)
7.5 Europe Growth Accelerators and Market Barriers
7.6 Europe Monoclonal Antibody Production Service Market Size by Country
7.6.1 Europe Revenue Trends by Country
7.6.2 Germany
7.6.3 France
7.6.4 U.K.
7.6.5 Italy
7.6.6 Russia
8 Asia-Pacific
8.1 Asia-Pacific Market Size (2020-2031)
8.2 Asia-Pacific Key Players Revenue in 2024
8.3 Asia-Pacific Monoclonal Antibody Production Service Market Size by Type (2020-2031)
8.4 Asia-Pacific Monoclonal Antibody Production Service Market Size by Application (2020-2031)
8.5 Asia-Pacific Growth Accelerators and Market Barriers
8.6 Asia-Pacific Monoclonal Antibody Production Service Market Size by Region
8.6.1 Asia-Pacific Revenue Trends by Region
8.7 China
8.8 Japan
8.9 South Korea
8.10 Australia
8.11 India
8.12 Southeast Asia
8.12.1 Indonesia
8.12.2 Vietnam
8.12.3 Malaysia
8.12.4 Philippines
8.12.5 Singapore
9 Central and South America
9.1 Central and South America Market Size (2020-2031)
9.2 Central and South America Key Players Revenue in 2024
9.3 Central and South America Monoclonal Antibody Production Service Market Size by Type (2020-2031)
9.4 Central and South America Monoclonal Antibody Production Service Market Size by Application (2020-2031)
9.5 Central and South America Investment Opportunities and Key Challenges
9.6 Central and South America Monoclonal Antibody Production Service Market Size by Country
9.6.1 Central and South America Revenue Trends by Country (2020 VS 2024 VS 2031)
9.6.2 Brazil
9.6.3 Argentina
10 Middle East and Africa
10.1 Middle East and Africa Market Size (2020-2031)
10.2 Middle East and Africa Key Players Revenue in 2024
10.3 Middle East and Africa Monoclonal Antibody Production Service Market Size by Type (2020-2031)
10.4 Middle East and Africa Monoclonal Antibody Production Service Market Size by Application (2020-2031)
10.5 Middle East and Africa Investment Opportunities and Key Challenges
10.6 Middle East and Africa Monoclonal Antibody Production Service Market Size by Country
10.6.1 Middle East and Africa Revenue Trends by Country (2020 VS 2024 VS 2031)
10.6.2 GCC Countries
10.6.3 Israel
10.6.4 Egypt
10.6.5 South Africa
11 Corporate Profile
11.1 Bon Opus Biosciences
11.1.1 Bon Opus Biosciences Corporation Information
11.1.2 Bon Opus Biosciences Business Overview
11.1.3 Bon Opus Biosciences Monoclonal Antibody Production Service Product Features and Attributes
11.1.4 Bon Opus Biosciences Monoclonal Antibody Production Service Revenue and Gross Margin (2020-2025)
11.1.5 Bon Opus Biosciences Monoclonal Antibody Production Service Revenue by Product in 2024
11.1.6 Bon Opus Biosciences Monoclonal Antibody Production Service Revenue by Application in 2024
11.1.7 Bon Opus Biosciences Monoclonal Antibody Production Service Revenue by Geographic Area in 2024
11.1.8 Bon Opus Biosciences Monoclonal Antibody Production Service SWOT Analysis
11.1.9 Bon Opus Biosciences Recent Developments
11.2 Biomatik
11.2.1 Biomatik Corporation Information
11.2.2 Biomatik Business Overview
11.2.3 Biomatik Monoclonal Antibody Production Service Product Features and Attributes
11.2.4 Biomatik Monoclonal Antibody Production Service Revenue and Gross Margin (2020-2025)
11.2.5 Biomatik Monoclonal Antibody Production Service Revenue by Product in 2024
11.2.6 Biomatik Monoclonal Antibody Production Service Revenue by Application in 2024
11.2.7 Biomatik Monoclonal Antibody Production Service Revenue by Geographic Area in 2024
11.2.8 Biomatik Monoclonal Antibody Production Service SWOT Analysis
11.2.9 Biomatik Recent Developments
11.3 ProSci, Inc
11.3.1 ProSci, Inc Corporation Information
11.3.2 ProSci, Inc Business Overview
11.3.3 ProSci, Inc Monoclonal Antibody Production Service Product Features and Attributes
11.3.4 ProSci, Inc Monoclonal Antibody Production Service Revenue and Gross Margin (2020-2025)
11.3.5 ProSci, Inc Monoclonal Antibody Production Service Revenue by Product in 2024
11.3.6 ProSci, Inc Monoclonal Antibody Production Service Revenue by Application in 2024
11.3.7 ProSci, Inc Monoclonal Antibody Production Service Revenue by Geographic Area in 2024
11.3.8 ProSci, Inc Monoclonal Antibody Production Service SWOT Analysis
11.3.9 ProSci, Inc Recent Developments
11.4 Sino Biological
11.4.1 Sino Biological Corporation Information
11.4.2 Sino Biological Business Overview
11.4.3 Sino Biological Monoclonal Antibody Production Service Product Features and Attributes
11.4.4 Sino Biological Monoclonal Antibody Production Service Revenue and Gross Margin (2020-2025)
11.4.5 Sino Biological Monoclonal Antibody Production Service Revenue by Product in 2024
11.4.6 Sino Biological Monoclonal Antibody Production Service Revenue by Application in 2024
11.4.7 Sino Biological Monoclonal Antibody Production Service Revenue by Geographic Area in 2024
11.4.8 Sino Biological Monoclonal Antibody Production Service SWOT Analysis
11.4.9 Sino Biological Recent Developments
11.5 Thermo Fisher Scientific
11.5.1 Thermo Fisher Scientific Corporation Information
11.5.2 Thermo Fisher Scientific Business Overview
11.5.3 Thermo Fisher Scientific Monoclonal Antibody Production Service Product Features and Attributes
11.5.4 Thermo Fisher Scientific Monoclonal Antibody Production Service Revenue and Gross Margin (2020-2025)
11.5.5 Thermo Fisher Scientific Monoclonal Antibody Production Service Revenue by Product in 2024
11.5.6 Thermo Fisher Scientific Monoclonal Antibody Production Service Revenue by Application in 2024
11.5.7 Thermo Fisher Scientific Monoclonal Antibody Production Service Revenue by Geographic Area in 2024
11.5.8 Thermo Fisher Scientific Monoclonal Antibody Production Service SWOT Analysis
11.5.9 Thermo Fisher Scientific Recent Developments
11.6 RayBiotech
11.6.1 RayBiotech Corporation Information
11.6.2 RayBiotech Business Overview
11.6.3 RayBiotech Monoclonal Antibody Production Service Product Features and Attributes
11.6.4 RayBiotech Monoclonal Antibody Production Service Revenue and Gross Margin (2020-2025)
11.6.5 RayBiotech Recent Developments
11.7 Cygnus Technologies
11.7.1 Cygnus Technologies Corporation Information
11.7.2 Cygnus Technologies Business Overview
11.7.3 Cygnus Technologies Monoclonal Antibody Production Service Product Features and Attributes
11.7.4 Cygnus Technologies Monoclonal Antibody Production Service Revenue and Gross Margin (2020-2025)
11.7.5 Cygnus Technologies Recent Developments
11.8 Sino Biological
11.8.1 Sino Biological Corporation Information
11.8.2 Sino Biological Business Overview
11.8.3 Sino Biological Monoclonal Antibody Production Service Product Features and Attributes
11.8.4 Sino Biological Monoclonal Antibody Production Service Revenue and Gross Margin (2020-2025)
11.8.5 Sino Biological Recent Developments
11.9 BosterBio
11.9.1 BosterBio Corporation Information
11.9.2 BosterBio Business Overview
11.9.3 BosterBio Monoclonal Antibody Production Service Product Features and Attributes
11.9.4 BosterBio Monoclonal Antibody Production Service Revenue and Gross Margin (2020-2025)
11.9.5 BosterBio Recent Developments
11.10 Abeomics
11.10.1 Abeomics Corporation Information
11.10.2 Abeomics Business Overview
11.10.3 Abeomics Monoclonal Antibody Production Service Product Features and Attributes
11.10.4 Abeomics Monoclonal Antibody Production Service Revenue and Gross Margin (2020-2025)
11.10.5 Company Ten Recent Developments
11.11 Merck
11.11.1 Merck Corporation Information
11.11.2 Merck Business Overview
11.11.3 Merck Monoclonal Antibody Production Service Product Features and Attributes
11.11.4 Merck Monoclonal Antibody Production Service Revenue and Gross Margin (2020-2025)
11.11.5 Merck Recent Developments
11.12 Cayman Chemical
11.12.1 Cayman Chemical Corporation Information
11.12.2 Cayman Chemical Business Overview
11.12.3 Cayman Chemical Monoclonal Antibody Production Service Product Features and Attributes
11.12.4 Cayman Chemical Monoclonal Antibody Production Service Revenue and Gross Margin (2020-2025)
11.12.5 Cayman Chemical Recent Developments
11.13 Hycult Biotech
11.13.1 Hycult Biotech Corporation Information
11.13.2 Hycult Biotech Business Overview
11.13.3 Hycult Biotech Monoclonal Antibody Production Service Product Features and Attributes
11.13.4 Hycult Biotech Monoclonal Antibody Production Service Revenue and Gross Margin (2020-2025)
11.13.5 Hycult Biotech Recent Developments
11.14 GenScript
11.14.1 GenScript Corporation Information
11.14.2 GenScript Business Overview
11.14.3 GenScript Monoclonal Antibody Production Service Product Features and Attributes
11.14.4 GenScript Monoclonal Antibody Production Service Revenue and Gross Margin (2020-2025)
11.14.5 GenScript Recent Developments
11.15 ProMab
11.15.1 ProMab Corporation Information
11.15.2 ProMab Business Overview
11.15.3 ProMab Monoclonal Antibody Production Service Product Features and Attributes
11.15.4 ProMab Monoclonal Antibody Production Service Revenue and Gross Margin (2020-2025)
11.15.5 ProMab Recent Developments
11.16 R&D Systems
11.16.1 R&D Systems Corporation Information
11.16.2 R&D Systems Business Overview
11.16.3 R&D Systems Monoclonal Antibody Production Service Product Features and Attributes
11.16.4 R&D Systems Monoclonal Antibody Production Service Revenue and Gross Margin (2020-2025)
11.16.5 R&D Systems Recent Developments
11.17 Rockland Immunochemicals
11.17.1 Rockland Immunochemicals Corporation Information
11.17.2 Rockland Immunochemicals Business Overview
11.17.3 Rockland Immunochemicals Monoclonal Antibody Production Service Product Features and Attributes
11.17.4 Rockland Immunochemicals Monoclonal Antibody Production Service Revenue and Gross Margin (2020-2025)
11.17.5 Rockland Immunochemicals Recent Developments
11.18 ProteoGenix
11.18.1 ProteoGenix Corporation Information
11.18.2 ProteoGenix Business Overview
11.18.3 ProteoGenix Monoclonal Antibody Production Service Product Features and Attributes
11.18.4 ProteoGenix Monoclonal Antibody Production Service Revenue and Gross Margin (2020-2025)
11.18.5 ProteoGenix Recent Developments
11.19 Evitria
11.19.1 Evitria Corporation Information
11.19.2 Evitria Business Overview
11.19.3 Evitria Monoclonal Antibody Production Service Product Features and Attributes
11.19.4 Evitria Monoclonal Antibody Production Service Revenue and Gross Margin (2020-2025)
11.19.5 Evitria Recent Developments
11.20 ProteoGenix
11.20.1 ProteoGenix Corporation Information
11.20.2 ProteoGenix Business Overview
11.20.3 ProteoGenix Monoclonal Antibody Production Service Product Features and Attributes
11.20.4 ProteoGenix Monoclonal Antibody Production Service Revenue and Gross Margin (2020-2025)
11.20.5 ProteoGenix Recent Developments
11.21 Beijing Abace Biotechnology
11.21.1 Beijing Abace Biotechnology Corporation Information
11.21.2 Beijing Abace Biotechnology Business Overview
11.21.3 Beijing Abace Biotechnology Monoclonal Antibody Production Service Product Features and Attributes
11.21.4 Beijing Abace Biotechnology Monoclonal Antibody Production Service Revenue and Gross Margin (2020-2025)
11.21.5 Beijing Abace Biotechnology Recent Developments
11.22 Zoonbio Biotechnology
11.22.1 Zoonbio Biotechnology Corporation Information
11.22.2 Zoonbio Biotechnology Business Overview
11.22.3 Zoonbio Biotechnology Monoclonal Antibody Production Service Product Features and Attributes
11.22.4 Zoonbio Biotechnology Monoclonal Antibody Production Service Revenue and Gross Margin (2020-2025)
11.22.5 Zoonbio Biotechnology Recent Developments
11.23 Beijing Biosynthesis Biotechnology
11.23.1 Beijing Biosynthesis Biotechnology Corporation Information
11.23.2 Beijing Biosynthesis Biotechnology Business Overview
11.23.3 Beijing Biosynthesis Biotechnology Monoclonal Antibody Production Service Product Features and Attributes
11.23.4 Beijing Biosynthesis Biotechnology Monoclonal Antibody Production Service Revenue and Gross Margin (2020-2025)
11.23.5 Beijing Biosynthesis Biotechnology Recent Developments
11.24 Cusabio
11.24.1 Cusabio Corporation Information
11.24.2 Cusabio Business Overview
11.24.3 Cusabio Monoclonal Antibody Production Service Product Features and Attributes
11.24.4 Cusabio Monoclonal Antibody Production Service Revenue and Gross Margin (2020-2025)
11.24.5 Cusabio Recent Developments
11.25 ChinaPeptides
11.25.1 ChinaPeptides Corporation Information
11.25.2 ChinaPeptides Business Overview
11.25.3 ChinaPeptides Monoclonal Antibody Production Service Product Features and Attributes
11.25.4 ChinaPeptides Monoclonal Antibody Production Service Revenue and Gross Margin (2020-2025)
11.25.5 ChinaPeptides Recent Developments
11.26 Detaibio
11.26.1 Detaibio Corporation Information
11.26.2 Detaibio Business Overview
11.26.3 Detaibio Monoclonal Antibody Production Service Product Features and Attributes
11.26.4 Detaibio Monoclonal Antibody Production Service Revenue and Gross Margin (2020-2025)
11.26.5 Detaibio Recent Developments
11.27 Atagenix Laboratories
11.27.1 Atagenix Laboratories Corporation Information
11.27.2 Atagenix Laboratories Business Overview
11.27.3 Atagenix Laboratories Monoclonal Antibody Production Service Product Features and Attributes
11.27.4 Atagenix Laboratories Monoclonal Antibody Production Service Revenue and Gross Margin (2020-2025)
11.27.5 Atagenix Laboratories Recent Developments
12 Monoclonal Antibody Production ServiceIndustry Chain Analysis
12.1 Monoclonal Antibody Production Service Industry Chain
12.2 Upstream Analysis
12.2.1 Upstream Key Suppliers
12.3 Middlestream Analysis
12.4 Downstream Sales Model and Distribution Networks
12.4.1 Sales Channels
12.4.2 Distributors
13 Monoclonal Antibody Production Service Market Dynamics
13.1 Industry Trends and Evolution
13.2 Market Growth Drivers and Emerging Opportunities
13.3 Market Challenges, Risks, and Restraints
14 Key Findings in the Global Monoclonal Antibody Production Service Study
15 Appendix
15.1 Research Methodology
15.1.1 Methodology/Research Approach
15.1.1.1 Research Programs/Design
15.1.1.2 Market Size Estimation
15.1.1.3 Market Breakdown and Data Triangulation
15.1.2 Data Source
15.1.2.1 Secondary Sources
15.1.2.2 Primary Sources
15.2 Author Details

List of Tables
Table 1. Global Monoclonal Antibody Production Service Market Size Growth Rate by Type, 2020 VS 2024 VS 2031 (US$ Million)
Table 2. Global Monoclonal Antibody Production Service Market Size Growth Rate by Application, 2020 VS 2024 VS 2031 (US$ Million)
Table 3. Global Monoclonal Antibody Production Service Revenue Grow Rate (CAGR) by Region: 2020 VS 2024 VS 2031 (US$ Million)
Table 4. Global Monoclonal Antibody Production Service Revenue by Region (2020-2025) & (US$ Million)
Table 5. Global Monoclonal Antibody Production Service Revenue by Region (2026-2031) & (US$ Million)
Table 6. Emerging Market Revenue Grow Rate (CAGR) by Country (2020 VS 2024 VS 2031) (US$ Million)
Table 7. Global Monoclonal Antibody Production Service Revenue by Players (2020-2025) & (US$ Million)
Table 8. Global Monoclonal Antibody Production Service Revenue Market Share by Players (2020-2025)
Table 9. Global Key Players’Ranking Shift (2023 vs. 2024) (Based on Revenue)
Table 10. Global Monoclonal Antibody Production Service by Player Tier (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Monoclonal Antibody Production Service as of 2024)
Table 11. Global Monoclonal Antibody Production Service Average Gross Margin (%) by Player (2020 VS 2024)
Table 12. Global Monoclonal Antibody Production Service Companies Headquarters
Table 13. Global Monoclonal Antibody Production Service Market Concentration Ratio (CR5 and HHI)
Table 14. Key Market Entrant/Exit (2020-2024) – Drivers & Impact Analysis
Table 15. Key Mergers & Acquisitions, Expansion Plans, R&D Investment
Table 16. Global Monoclonal Antibody Production Service Revenue by Type (2020-2025) & (US$ Million)
Table 17. Global Monoclonal Antibody Production Service Revenue by Type (2026-2031) & (US$ Million)
Table 18. Key Product Attributes and Differentiation
Table 19. Global Monoclonal Antibody Production Service Revenue by Application (2020-2025) & (US$ Million)
Table 20. Global Monoclonal Antibody Production Service Revenue by Application (2026-2031) & (US$ Million)
Table 21. Monoclonal Antibody Production Service High-Growth Sectors Demand CAGR (2024-2031)
Table 22. Top Customers by Region
Table 23. Top Customers by Application
Table 24. North America Monoclonal Antibody Production Service Growth Accelerators and Market Barriers
Table 25. North America Monoclonal Antibody Production Service Revenue Grow Rate (CAGR) by Country (2020 VS 2024 VS 2031) (US$ Million)
Table 26. Europe Monoclonal Antibody Production Service Growth Accelerators and Market Barriers
Table 27. Europe Monoclonal Antibody Production Service Revenue Grow Rate (CAGR) by Country: 2020 VS 2024 VS 2031 (US$ Million)
Table 28. Asia-Pacific Monoclonal Antibody Production Service Growth Accelerators and Market Barriers
Table 29. Asia-Pacific Monoclonal Antibody Production Service Revenue Grow Rate (CAGR) by Region: 2020 VS 2024 VS 2031 (US$ Million)
Table 30. Central and South America Monoclonal Antibody Production Service Investment Opportunities and Key Challenges
Table 31. Central and South America Monoclonal Antibody Production Service Revenue Grow Rate (CAGR) by Country (2020 VS 2024 VS 2031) (US$ Million)
Table 32. Middle East and Africa Monoclonal Antibody Production Service Investment Opportunities and Key Challenges
Table 33. Middle East and Africa Monoclonal Antibody Production Service Revenue Grow Rate (CAGR) by Country (2020 VS 2024 VS 2031) (US$ Million)
Table 34. Bon Opus Biosciences Corporation Information
Table 35. Bon Opus Biosciences Description and Major Businesses
Table 36. Bon Opus Biosciences Product Features and Attributes
Table 37. Bon Opus Biosciences Revenue (US$ Million) and Gross Margin (2020-2025)
Table 38. Bon Opus Biosciences Revenue Proportion by Product in 2024
Table 39. Bon Opus Biosciences Revenue Proportion by Application in 2024
Table 40. Bon Opus Biosciences Revenue Proportion by Geographic Area in 2024
Table 41. Bon Opus Biosciences Monoclonal Antibody Production Service SWOT Analysis
Table 42. Bon Opus Biosciences Recent Developments
Table 43. Biomatik Corporation Information
Table 44. Biomatik Description and Major Businesses
Table 45. Biomatik Product Features and Attributes
Table 46. Biomatik Revenue (US$ Million) and Gross Margin (2020-2025)
Table 47. Biomatik Revenue Proportion by Product in 2024
Table 48. Biomatik Revenue Proportion by Application in 2024
Table 49. Biomatik Revenue Proportion by Geographic Area in 2024
Table 50. Biomatik Monoclonal Antibody Production Service SWOT Analysis
Table 51. Biomatik Recent Developments
Table 52. ProSci, Inc Corporation Information
Table 53. ProSci, Inc Description and Major Businesses
Table 54. ProSci, Inc Product Features and Attributes
Table 55. ProSci, Inc Revenue (US$ Million) and Gross Margin (2020-2025)
Table 56. ProSci, Inc Revenue Proportion by Product in 2024
Table 57. ProSci, Inc Revenue Proportion by Application in 2024
Table 58. ProSci, Inc Revenue Proportion by Geographic Area in 2024
Table 59. ProSci, Inc Monoclonal Antibody Production Service SWOT Analysis
Table 60. ProSci, Inc Recent Developments
Table 61. Sino Biological Corporation Information
Table 62. Sino Biological Description and Major Businesses
Table 63. Sino Biological Product Features and Attributes
Table 64. Sino Biological Revenue (US$ Million) and Gross Margin (2020-2025)
Table 65. Sino Biological Revenue Proportion by Product in 2024
Table 66. Sino Biological Revenue Proportion by Application in 2024
Table 67. Sino Biological Revenue Proportion by Geographic Area in 2024
Table 68. Sino Biological Monoclonal Antibody Production Service SWOT Analysis
Table 69. Sino Biological Recent Developments
Table 70. Thermo Fisher Scientific Corporation Information
Table 71. Thermo Fisher Scientific Description and Major Businesses
Table 72. Thermo Fisher Scientific Product Features and Attributes
Table 73. Thermo Fisher Scientific Revenue (US$ Million) and Gross Margin (2020-2025)
Table 74. Thermo Fisher Scientific Revenue Proportion by Product in 2024
Table 75. Thermo Fisher Scientific Revenue Proportion by Application in 2024
Table 76. Thermo Fisher Scientific Revenue Proportion by Geographic Area in 2024
Table 77. Thermo Fisher Scientific Monoclonal Antibody Production Service SWOT Analysis
Table 78. Thermo Fisher Scientific Recent Developments
Table 79. RayBiotech Corporation Information
Table 80. RayBiotech Description and Major Businesses
Table 81. RayBiotech Product Features and Attributes
Table 82. RayBiotech Revenue (US$ Million) and Gross Margin (2020-2025)
Table 83. RayBiotech Recent Developments
Table 84. Cygnus Technologies Corporation Information
Table 85. Cygnus Technologies Description and Major Businesses
Table 86. Cygnus Technologies Product Features and Attributes
Table 87. Cygnus Technologies Revenue (US$ Million) and Gross Margin (2020-2025)
Table 88. Cygnus Technologies Recent Developments
Table 89. Sino Biological Corporation Information
Table 90. Sino Biological Description and Major Businesses
Table 91. Sino Biological Product Features and Attributes
Table 92. Sino Biological Revenue (US$ Million) and Gross Margin (2020-2025)
Table 93. Sino Biological Recent Developments
Table 94. BosterBio Corporation Information
Table 95. BosterBio Description and Major Businesses
Table 96. BosterBio Product Features and Attributes
Table 97. BosterBio Revenue (US$ Million) and Gross Margin (2020-2025)
Table 98. BosterBio Recent Developments
Table 99. Abeomics Corporation Information
Table 100. Abeomics Description and Major Businesses
Table 101. Abeomics Product Features and Attributes
Table 102. Abeomics Revenue (US$ Million) and Gross Margin (2020-2025)
Table 103. Abeomics Recent Developments
Table 104. Merck Corporation Information
Table 105. Merck Description and Major Businesses
Table 106. Merck Product Features and Attributes
Table 107. Merck Revenue (US$ Million) and Gross Margin (2020-2025)
Table 108. Merck Recent Developments
Table 109. Cayman Chemical Corporation Information
Table 110. Cayman Chemical Description and Major Businesses
Table 111. Cayman Chemical Product Features and Attributes
Table 112. Cayman Chemical Revenue (US$ Million) and Gross Margin (2020-2025)
Table 113. Cayman Chemical Recent Developments
Table 114. Hycult Biotech Corporation Information
Table 115. Hycult Biotech Description and Major Businesses
Table 116. Hycult Biotech Product Features and Attributes
Table 117. Hycult Biotech Revenue (US$ Million) and Gross Margin (2020-2025)
Table 118. Hycult Biotech Recent Developments
Table 119. GenScript Corporation Information
Table 120. GenScript Description and Major Businesses
Table 121. GenScript Product Features and Attributes
Table 122. GenScript Revenue (US$ Million) and Gross Margin (2020-2025)
Table 123. GenScript Recent Developments
Table 124. ProMab Corporation Information
Table 125. ProMab Description and Major Businesses
Table 126. ProMab Product Features and Attributes
Table 127. ProMab Revenue (US$ Million) and Gross Margin (2020-2025)
Table 128. ProMab Recent Developments
Table 129. R&D Systems Corporation Information
Table 130. R&D Systems Description and Major Businesses
Table 131. R&D Systems Product Features and Attributes
Table 132. R&D Systems Revenue (US$ Million) and Gross Margin (2020-2025)
Table 133. R&D Systems Recent Developments
Table 134. Rockland Immunochemicals Corporation Information
Table 135. Rockland Immunochemicals Description and Major Businesses
Table 136. Rockland Immunochemicals Product Features and Attributes
Table 137. Rockland Immunochemicals Revenue (US$ Million) and Gross Margin (2020-2025)
Table 138. Rockland Immunochemicals Recent Developments
Table 139. ProteoGenix Corporation Information
Table 140. ProteoGenix Description and Major Businesses
Table 141. ProteoGenix Product Features and Attributes
Table 142. ProteoGenix Revenue (US$ Million) and Gross Margin (2020-2025)
Table 143. ProteoGenix Recent Developments
Table 144. Evitria Corporation Information
Table 145. Evitria Description and Major Businesses
Table 146. Evitria Product Features and Attributes
Table 147. Evitria Revenue (US$ Million) and Gross Margin (2020-2025)
Table 148. Evitria Recent Developments
Table 149. ProteoGenix Corporation Information
Table 150. ProteoGenix Description and Major Businesses
Table 151. ProteoGenix Product Features and Attributes
Table 152. ProteoGenix Revenue (US$ Million) and Gross Margin (2020-2025)
Table 153. ProteoGenix Recent Developments
Table 154. Beijing Abace Biotechnology Corporation Information
Table 155. Beijing Abace Biotechnology Description and Major Businesses
Table 156. Beijing Abace Biotechnology Product Features and Attributes
Table 157. Beijing Abace Biotechnology Revenue (US$ Million) and Gross Margin (2020-2025)
Table 158. Beijing Abace Biotechnology Recent Developments
Table 159. Zoonbio Biotechnology Corporation Information
Table 160. Zoonbio Biotechnology Description and Major Businesses
Table 161. Zoonbio Biotechnology Product Features and Attributes
Table 162. Zoonbio Biotechnology Revenue (US$ Million) and Gross Margin (2020-2025)
Table 163. Zoonbio Biotechnology Recent Developments
Table 164. Beijing Biosynthesis Biotechnology Corporation Information
Table 165. Beijing Biosynthesis Biotechnology Description and Major Businesses
Table 166. Beijing Biosynthesis Biotechnology Product Features and Attributes
Table 167. Beijing Biosynthesis Biotechnology Revenue (US$ Million) and Gross Margin (2020-2025)
Table 168. Beijing Biosynthesis Biotechnology Recent Developments
Table 169. Cusabio Corporation Information
Table 170. Cusabio Description and Major Businesses
Table 171. Cusabio Product Features and Attributes
Table 172. Cusabio Revenue (US$ Million) and Gross Margin (2020-2025)
Table 173. Cusabio Recent Developments
Table 174. ChinaPeptides Corporation Information
Table 175. ChinaPeptides Description and Major Businesses
Table 176. ChinaPeptides Product Features and Attributes
Table 177. ChinaPeptides Revenue (US$ Million) and Gross Margin (2020-2025)
Table 178. ChinaPeptides Recent Developments
Table 179. Detaibio Corporation Information
Table 180. Detaibio Description and Major Businesses
Table 181. Detaibio Product Features and Attributes
Table 182. Detaibio Revenue (US$ Million) and Gross Margin (2020-2025)
Table 183. Detaibio Recent Developments
Table 184. Atagenix Laboratories Corporation Information
Table 185. Atagenix Laboratories Description and Major Businesses
Table 186. Atagenix Laboratories Product Features and Attributes
Table 187. Atagenix Laboratories Revenue (US$ Million) and Gross Margin (2020-2025)
Table 188. Atagenix Laboratories Recent Developments
Table 189. Raw Materials Key Suppliers
Table 190. Distributors List
Table 191. Market Trends and Market Evolution
Table 192. Market Drivers and Opportunities
Table 193. Market Challenges, Risks, and Restraints
Table 194. Research Programs/Design for This Report
Table 195. Key Data Information from Secondary Sources
Table 196. Key Data Information from Primary Sources


List of Figures
Figure 1. Monoclonal Antibody Production Service Product Picture
Figure 2. Global Monoclonal Antibody Production Service Market Size Growth Rate by Type, 2020 VS 2024 VS 2031 (US$ Million)
Figure 3. Rabbit Monoclonal Antibodies Product Picture
Figure 4. Mouse Monoclonal Antibodies Product Picture
Figure 5. Human Monoclonal Antibodies Product Picture
Figure 6. Others Product Picture
Figure 7. Global Monoclonal Antibody Production Service Market Size Growth Rate by Application, 2020 VS 2024 VS 2031 (US$ Million)
Figure 8. Biotechnology
Figure 9. Medical
Figure 10. University
Figure 11. Others
Figure 12. Monoclonal Antibody Production Service Report Years Considered
Figure 13. Global Monoclonal Antibody Production Service Revenue, (US$ Million), 2020 VS 2024 VS 2031
Figure 14. Global Monoclonal Antibody Production Service Revenue (2020-2031) & (US$ Million)
Figure 15. Global Monoclonal Antibody Production Service Revenue (CAGR) by Region: 2020 VS 2024 VS 2031 (US$ Million)
Figure 16. Global Monoclonal Antibody Production Service Revenue Market Share by Region (2020-2031)
Figure 17. Global Monoclonal Antibody Production Service Revenue Market Share Ranking (2024)
Figure 18. Tier Distribution by Revenue Contribution (2020 VS 2024)
Figure 19. Rabbit Monoclonal Antibodies Revenue Market Share by Player in 2024
Figure 20. Mouse Monoclonal Antibodies Revenue Market Share by Player in 2024
Figure 21. Human Monoclonal Antibodies Revenue Market Share by Player in 2024
Figure 22. Others Revenue Market Share by Player in 2024
Figure 23. Global Monoclonal Antibody Production Service Revenue Market Share by Type (2020-2031)
Figure 24. Global Monoclonal Antibody Production Service Revenue Market Share by Application (2020-2031)
Figure 25. North America Monoclonal Antibody Production Service Revenue YoY (2020-2031) & (US$ Million)
Figure 26. North America Top 5 Players Monoclonal Antibody Production Service Revenue (US$ Million) in 2024
Figure 27. North America Monoclonal Antibody Production Service Revenue (US$ Million) by Type (2020 - 2031)
Figure 28. North America Monoclonal Antibody Production Service Revenue (US$ Million) by Application (2020-2031)
Figure 29. US Monoclonal Antibody Production Service Revenue (2020-2031) & (US$ Million)
Figure 30. Canada Monoclonal Antibody Production Service Revenue (2020-2031) & (US$ Million)
Figure 31. Mexico Monoclonal Antibody Production Service Revenue (2020-2031) & (US$ Million)
Figure 32. Europe Monoclonal Antibody Production Service Revenue YoY (2020-2031) & (US$ Million)
Figure 33. Europe Top 5 Players Monoclonal Antibody Production Service Revenue (US$ Million) in 2024
Figure 34. Europe Monoclonal Antibody Production Service Revenue (US$ Million) by Type (2020-2031)
Figure 35. Europe Monoclonal Antibody Production Service Revenue (US$ Million) by Application (2020-2031)
Figure 36. Germany Monoclonal Antibody Production Service Revenue (2020-2031) & (US$ Million)
Figure 37. France Monoclonal Antibody Production Service Revenue (2020-2031) & (US$ Million)
Figure 38. U.K. Monoclonal Antibody Production Service Revenue (2020-2031) & (US$ Million)
Figure 39. Italy Monoclonal Antibody Production Service Revenue (2020-2031) & (US$ Million)
Figure 40. Russia Monoclonal Antibody Production Service Revenue (2020-2031) & (US$ Million)
Figure 41. Asia-Pacific Monoclonal Antibody Production Service Revenue YoY (2020-2031) & (US$ Million)
Figure 42. Asia-Pacific Top 8 Players Monoclonal Antibody Production Service Revenue (US$ Million) in 2024
Figure 43. Asia-Pacific Monoclonal Antibody Production Service Revenue (US$ Million) by Type (2020-2031)
Figure 44. Asia-Pacific Monoclonal Antibody Production Service Revenue (US$ Million) by Application (2020-2031)
Figure 45. Indonesia Monoclonal Antibody Production Service Revenue (2020-2031) & (US$ Million)
Figure 46. Japan Monoclonal Antibody Production Service Revenue (2020-2031) & (US$ Million)
Figure 47. South Korea Monoclonal Antibody Production Service Revenue (2020-2031) & (US$ Million)
Figure 48. Australia Monoclonal Antibody Production Service Revenue (2020-2031) & (US$ Million)
Figure 49. India Monoclonal Antibody Production Service Revenue (2020-2031) & (US$ Million)
Figure 50. Indonesia Monoclonal Antibody Production Service Revenue (2020-2031) & (US$ Million)
Figure 51. Vietnam Monoclonal Antibody Production Service Revenue (2020-2031) & (US$ Million)
Figure 52. Malaysia Monoclonal Antibody Production Service Revenue (2020-2031) & (US$ Million)
Figure 53. Philippines Monoclonal Antibody Production Service Revenue (2020-2031) & (US$ Million)
Figure 54. Singapore Monoclonal Antibody Production Service Revenue (2020-2031) & (US$ Million)
Figure 55. Central and South America Monoclonal Antibody Production Service Revenue YoY (2020-2031) & (US$ Million)
Figure 56. Central and South America Top 5 Players Monoclonal Antibody Production Service Revenue (US$ Million) in 2024
Figure 57. Central and South America Monoclonal Antibody Production Service Revenue (US$ Million) by Type (2020-2031)
Figure 58. Central and South America Monoclonal Antibody Production Service Revenue (US$ Million) by Application (2020-2031)
Figure 59. Brazil Monoclonal Antibody Production Service Revenue (2020-2025) & (US$ Million)
Figure 60. Argentina Monoclonal Antibody Production Service Revenue (2020-2025) & (US$ Million)
Figure 61. Middle East and Africa Monoclonal Antibody Production Service Revenue YoY (2020-2031) & (US$ Million)
Figure 62. Middle East and Africa Top 5 Players Monoclonal Antibody Production Service Revenue (US$ Million) in 2024
Figure 63. South America Monoclonal Antibody Production Service Revenue (US$ Million) by Type (2020-2031)
Figure 64. Middle East and Africa Monoclonal Antibody Production Service Revenue (US$ Million) by Application (2020-2031)
Figure 65. GCC Countries Monoclonal Antibody Production Service Revenue (2020-2025) & (US$ Million)
Figure 66. Israel Monoclonal Antibody Production Service Revenue (2020-2025) & (US$ Million)
Figure 67. Egypt Monoclonal Antibody Production Service Revenue (2020-2025) & (US$ Million)
Figure 68. South Africa Monoclonal Antibody Production Service Revenue (2020-2025) & (US$ Million)
Figure 69. Monoclonal Antibody Production Service Industry Chain Mapping
Figure 70. Channels of Distribution (Direct Vs Distribution)
Figure 71. Bottom-up and Top-down Approaches for This Report
Figure 72. Data Triangulation
Figure 73. Key Executives Interviewed

Your Name

Your E-mail

Your message

Submit